Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 312 participants.
Also called NCT03770728
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 312 participants
- Registry
-
NCT03770728
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, China, Taiwan
- Registry status
- Terminated
Technical summary
Registry record NCT03770728. Randomized; quadruple masking; primary purpose treatment. Start 2019-08-01 (actual); primary completion 2020-11-28 (actual). Results posted on 2021-12-02.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
- Acronym
- AMPLITUDE-S
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Efpeglenatide SAR439977
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Background therapy: Metformin alone or in combination with SU
- Lead sponsor
- Sanofi
- Collaborator
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct03770728- Content hash
6dec067cf1b5625d44f5027dc18f261d6eb5f511db350b1abb35842312c2fae9